AzTrials
AzTrials

Human Papilloma VirusGLUCANVIRNCT04781023

Efficacy of an Intravaginal Treatment With Carboxymethyl-β-glucan and Polycarbophil in HR-HPV Clearance

A study testing Colpofix in people with Human Papilloma Virus, run by Uriach Consumer Healthcare at 1 site in Spain.

Unknown status

Status not confirmed. The sponsor has not verified this record for over two years, so it may be out of date.

Official record
Search all trials

Trial summary

These treatments are beta-glucans, polysaccharides of beta-D-glucose that, can influence the clearance of HPV infection. The objective of this study is to evaluate the efficacy of a gel with Carboxymethyl - β -Glucan and polycarbophil when applied intravaginally regarding the clearance of HPV infection. Read more about this study

Who is it for?
Ages 30 to 40 years, women only
Conditions the study is for
Human Papilloma Virus
What is being tested?
Colpofix
Type of treatment
Medical device
Could I receive a placebo?
No, everyone receives an active treatment
How many people
200 participants
Where
1 siteSpain
Study dates
15 Jun 2021to 1 Sep 2023
Phase
Interventional
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 30 to 40 years
  • Women only
  • No healthy volunteers
  • Adult

Who may be able to join

  • Sexually active women
  • between 30 and 40 years old
  • HR-HPV+ test (genotypes 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66 and 68)
  • normal cytology

Who cannot join

  • Current or previous pregnancy ended before six weeks in relation to the start of the study.
  • Vaccination against HPV.
  • Clinically relevant pathology linked to immunodeficiency.
  • Immunosuppressive treatment active or finished before six months in relation to the start of the study. In the specific case of corticosteroids, all women who are receiving corticosteroid treatment currently or recently (defined as the two weeks prior to the start of the study) or if she has received 2 or more cycles of corticosteroids in equal or greater than 20 mg / day of predsinone (or equivalent) orally or parenterally, for one week duration at least in the year prior to the start of the study. The use of inhaled corticosteroids, Nasal or topical are not exclusion criteria.
  • Undiagnosed abnormal genital bleeding.
  • Total hysterectomy.
Show all 11Show fewer
  • Presence of genital warts and other symptomatic vulvovaginal infections.
  • Documented history of cervical pathology caused by HPV.
  • Current systemic and / or gynecological disease that contraindicates the use of Colpofix.
  • Contraindications to the use of Colpofix or known allergies to any of its components
  • Simultaneous participating in a clinical study of an investigational drug or that could interfere with the use of Colpofix.

Trial locations and contacts

1 site in 1 country.

Jesus de la Fuente Valero, MD contact

+34669264966

jesus.fuente@salud.madrid.org

Spain1 site
  • Hospital Universitario Infanta Leonor

    Vallecas, Madrid, 28031

Other trials in Spain

About this study

Official title: Evaluation of the Efficacy of an Intravaginal Treatment With Carboxymethyl-β-glucan and Polycarbophil in the Clearance of High-risk Human Papillomavirus Infection

These treatments are beta-glucans, polysaccharides of beta-D-glucose that, can influence the clearance of HPV infection. The objective of this study is to evaluate the efficacy of a gel with Carboxymethyl - β -Glucan and polycarbophil when applied intravaginally regarding the clearance of HPV infection.

Read the detailed description

Background

Human papillomavirus (HPV) infection represents a significant source of morbidity and mortality worldwide. High-risk oncogenic HPVs cause 99.7% of cervical cancers. 80% of sexually active women will be infected with HPV at some point in their life. Most of these infections are transitory and only if they are persistent and caused by a high-risk oncogenic HPV are they an important risk factor for the development of cervical intraepithelial lesions and invasive cervical cancer. Immunity plays a key factor in eliminating HPV infection. The innate immune response constitutes the first line of defense against infection during the early stages of infection, promoting a cytokine-mediated inflammatory response which links innate immunity with the adaptive immune response. HPV evasion of these immune defense mechanisms is critical for the persistence of the infection and leads to the development of preneoplastic lesions and ultimately to cervical cancer. Through the use of adjuvant medical treatments represents a therapeutic strategy to avoid the evasion mechanisms of HPV. One of these most promising treatments is beta-glucans that seem capable of affecting the course of HPV infection.

Justification

β-glucans are a very diverse heterogeneous group of polysaccharides made up of D-glucose monomers linked by β-type glycosidic bonds.

β-glucans have been previously described in bacteria, fungi, yeasts (including brewer's yeast), plants and algae, where they play an important structural role in the cell wall or reservoir.

There are more than 6000 studies that have described the effects of glucans, mainly those of β-1,3 bonds, such as anti-inflammatory and antimicrobial properties. At least 4 receptors have been identified in mammals for the recognition of these molecules: lactosylceramide, scavengers, complement receptor 3 and dectin-1.

Commercial production of 1,3-β-glucans has been carried out by cultivating bacteria, yeasts, fungi, and plants.

Recent studies focusing on their influence on cytotoxic and helper T cells, APCs, inflammatory pathways, and oxidative burst (using reactive oxygen species to kill cells) have revealed that they may also have some anti-cancer properties. Some efforts have been made in the field of cervical cancer prevention and it has been shown that β-glucans can also affect HPV infection. Carboxymethyl β-glucan gel treatment was studied in a group of affected individuals by CIN1. This case-control study demonstrated that it has an anti-cervical cancer role in CIN1 regression. In 2010, two studies were conducted on the topic of "the influence of β-glucans" on HPV-related lesions in the genital area. "The first study found that β-glucans can treat infection-related lesions and the second study revealed the efficacy of beta-glucan treatment for HPVCIN1 lesions. These studies suggested that, in addition to the anticancer effects of beta-glucans, they also have some effects on infection by HPV, the main cause of cervical cancer.

On the other hand, the local treatment of vaginal problems has been known since ancient times, and more recently it has been favored over oral treatments due to the achievement of higher local concentrations of drugs and fewer interactions of the active principles and interference with the gastrointestinal tract. Vaginal products are marketed in the form of tablets, capsules, pessaries or ovules and semisolid forms (creams, ointments and gels), being available as products for the treatment and prevention of vaginal infections. Conventional dosage forms are associated with poor distribution and retention, primarily due to the self-cleaning action of the vagina. Among the commercialized dosage forms, semisolids, in particular gels, have been considered the preferred ones as they spread easily over the vaginal surface area. Additionally, due to their high water content, they confer moisture and lubrication effects that help alleviate the symptoms of conditions associated with vaginal dryness.

Bioadhesion refers to the binding of natural or synthetic macromolecules to a biological tissue. Mucoadhesion is considered a particular case of bioadhesion whenever the binding occurs with mucous glycoproteins (mucin) or mucous membranes. The translation of these concepts into pharmaceutical technology has been widely studied through the use of bioadhesive polymers. Among the most used in vaginal formulations are polyacrylates (such as carbomers and polycarbophils), cellulose derivatives (hydroxyethylcellulose (HEC), hydroxypropylcellulose (HPC), hydroxypropylmethylcellulose (HPMC), etc.), chitosan, hyaluronic acid and its derivatives, starch, pectin, natural gums and sodium alginate. In addition to increasing the retention time of vaginal formulations, thus promoting therapeutic duration and efficacy and improving patient comfort and adherence, these excipients also allow controlled drug release, thus improving local pharmacokinetics.

Polycarbophil and carbomer (polyacrylate) vaginal applications have been specially studied in vitro and in vivo, and have been included in various proprietary formulations as well as actual marketed products. These polymers have the additional advantage of being acidic, allowing the correction and maintenance of vaginal pH, and their acid-buffering capacity has been explored as a strategy for the treatment of bacterial vaginosis and the prevention of vaginosis recurrence for prevent the proliferation of pathogens, while promoting the restoration of the protective flora of Lactobacillus.

Polycarbophil, in particular, has been widely used for its bioadhesive properties, especially after a 1-3% polycarbophil gel was shown to maintain vaginal acidity for 3-4 days after a single application in postmenopausal women and A polycarbophil-carbomer vaginal gel was proven in women with suspected and confirmed bacterial vaginosis to show a reduction in vaginal pH in both trials, and a high clinical cure rate in confirmed vaginosis cases compared to placebo.

The objective of this study is to evaluate the efficacy of a gel with Carboxymethyl - β -Glucan and polycarbophil when applied intravaginally regarding the clearance of HPV infection.

Being tested
Colpofix
Keywords
Human Papilomavirus, Cervical cancer, Cervial lesions, High-Risk Papillomavirus, beta-glucans
Medical subject headings
Uterine Cervical Neoplasms

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • ColpofixDevice

    Intravaginal gel with carboxymtheyl beta-glucan and polycabophil. Posology: 1 application / day x 20 days, rest 10. Repeat 20 x 3 cycles

Study groups in NCT04781023
Study groupRoleWhat they receive
Intervention (Colpofix)Experimentalintravaginal gel with carboxymtheyl beta-glucan and polycabophil
Receives: Device: Colpofix
ControlNo interventionNo intervention (standard of care)

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Change in the clearance of high-risk HPV infection in women without cytological alterations upon local treatment with carboxymethyl-β-glucan and polycarbophilon the clearance of high-risk HPV infection in women without cytological alterations.

    Evaluation of the change in HPV clearance by HPV PCR test

    Measured: 24 months (6, 12, 18 and 24 months)

Secondary outcomes (5)
  1. Determine the effect of local treatment with carboxymethyl - β-glucan and polycarbophil on the clearance rate of HPV

    Evaluation of HPV clearance rate by HPV PCR test

    Measured: 24 months (6, 12, 18 and 24 months)

  2. Determine the effect of local treatment with carboxymethyl - β-glucan and polycarbophil on the clearance time of HPV

    Evaluation of HPV clearance time by HPV PCR test

    Measured: 24 months (6, 12, 18 and 24 months)

  3. Change on the incidence of cytological alterations upon local treatment with carboxymethyl - β-glucan and polycarbophil during the follow-up time

    change in the incidence of cytological alterations development by cytology

    Measured: 24 months (6, 12, 18 and 24 months)

  4. Safety assessment: incidence of Adverse Events

    Safety assessment by means of a dichotomous questionnaire and description of the adverse event, if any

    Measured: 24 months

  5. Tolerance assessment: measurement of treatment acceptance by subjects

    Tolerance acceptance by means of a dochotomous questionnaire

    Measured: 24 months

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted4 Mar 2021
  2. Study start15 Jun 2021 (estimated)
  3. Primary completion1 Sep 2023 (estimated)
  4. Study completion1 Sep 2023 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Model description
Interventional, longitudinal, prospective, open label trial with a control group with randomized, consecutive recruitment for each group, to evaluate the safety and efficacy of carboxymethyl-beta-glucan and polycarbophil as a treatment for high-risk HPV infection in women without cytological alterations.
Masking
None (open label)
Enrolment
200 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT04781023
Sponsor's protocol ID
GLUCANVIR V1 15/7/2020
Acronym
GLUCANVIR
Status last verified
Jun 2021
First submitted
22 Feb 2021
Last updated
10 Jun 2021
Results posted
No
Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No

Publications

  • Geller A, Shrestha R, Yan J. Yeast-Derived beta-Glucan in Cancer: Novel Uses of a Traditional Therapeutic. Int J Mol Sci. 2019 Jul 24;20(15):3618. doi: 10.3390/ijms20153618.

    PubMed 31344853
  • Chaichian S, Moazzami B, Sadoughi F, Haddad Kashani H, Zaroudi M, Asemi Z. Functional activities of beta-glucans in the prevention or treatment of cervical cancer. J Ovarian Res. 2020 Mar 5;13(1):24. doi: 10.1186/s13048-020-00626-7.

    PubMed 32138756
  • Stentella P, Biamonti A, Carraro C, Inghirami P, Mancino P, Pietrangeli D, Votano S, Lazzari P, DE Medici C. Efficacy of carboxymethyl beta-glucan in cervical intraepithelial neoplasia: a retrospective, case-control study. Minerva Ginecol. 2017 Oct;69(5):425-430. doi: 10.23736/S0026-4784.17.04053-9.

    PubMed 28675291
  • Pietrantoni E, Signore F, Berardi G, Donadio F, Donadio C. [Role of beta-glucan in the treatment of recurrent candidiasis and HPV-correlated lesions and reparative process of epidermis]. Minerva Ginecol. 2010 Feb;62(1):1-5. Italian.

    PubMed 20186110
  • Scardamaglia P, Carraro C, Mancino P, Stentella P. [Effectiveness of the treatment with beta-glucan in the HPV-CIN 1 lesions]. Minerva Ginecol. 2010 Oct;62(5):389-93. Italian.

    PubMed 20938424
  • Palmeira-de-Oliveira R, Palmeira-de-Oliveira A, Martinez-de-Oliveira J. New strategies for local treatment of vaginal infections. Adv Drug Deliv Rev. 2015 Sep 15;92:105-22. doi: 10.1016/j.addr.2015.06.008. Epub 2015 Jul 2.

    PubMed 26144995
  • Fiorilli A, Molteni B, Milani M. Successful treatment of bacterial vaginosis with a policarbophil-carbopol acidic vaginal gel: results from a randomised double-blind, placebo-controlled trial. Eur J Obstet Gynecol Reprod Biol. 2005 Jun 1;120(2):202-5. doi: 10.1016/j.ejogrb.2004.10.011.

    PubMed 15925053

Questions about this trial

What is this clinical trial studying?

A study testing Colpofix in people with Human Papilloma Virus, run by Uriach Consumer Healthcare at 1 site in Spain.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 4 inclusion and 11 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: status not confirmed, as of the sponsor's last update on 10 Jun 2021. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Spain. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

Results are not available in the source record.

How can a doctor refer a patient or contact the research team?

Contact Jesus de la Fuente Valero, MD (+34669264966, jesus.fuente@salud.madrid.org), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Change in the clearance of high-risk HPV infection in women without cytological alterations upon local treatment with carboxymethyl-β-glucan and polycarbophilon the clearance of high-risk HPV infection in women without cytological alterations. (time frame: 24 months (6, 12, 18 and 24 months)). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT04781023, which also lists 7 linked publications.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 10 Jun 2021; AzTrials last refreshed its copy on 8 Nov 2026.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in